Xbrane Biopharma now has an April 2024 date for US Food and Drug Administration action on its re-filed ranibizumab biosimilar, which it resubmitted to the agency earlier this year following a knockback in 2022.
Xbrane Gets Action Date As Ranibizumab Filing Accepted By FDA
Gains BsUFA Goal Date Of 21 April 2024 For Biosimilar Rival To Lucentis
Xbrane has announced the formal acceptance by the US FDA of its re-filed ranibizumab biosimilar, developed in collaboration with Stada and licensed in North America to Bausch + Lomb.
More from Biosimilars
More from Products
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.